Clay Nolan Presents CoLabs at LSI USA ‘23

Transcription

Clay Nolan  0:05  

CoLabs Medical, we're creating the AED of airway management and ventilation. Everybody's familiar with AED and how it went from an invasive diet device, diseases and emergency department to something that a bystander could deploy at a airport, or even at a stadium. Picture this picture procedure procedure as complicated as this simplified to the point where a child can do it. Not only that picture delivering a therapy that's superior to the gold standard today. I didn't get a tutorial on this given second. Nope. Bullseye, cardiac arrest, still one of the largest killers in the US 500,000 events, excuse me 500,000 events each year, the chances of walking out neurologically intact are one out of 10. So of course, there's been a lot of research to improve these art, excuse me. Of course, there's been a lot of research to improve these odds of cardiac stress and the survival. But the rates of survival haven't improved. In the past 15 years, the American Heart Association really went out and found out that the biggest cause one of the biggest decreases in this rival cardiac arrest is related to airway management and ventilation. And what they found out is there's two main problems with airway ventilation, excuse me, airway management, and ventilation. First, is that intubation is a complex problem, and 107 are misplaced out of hospital, which suffocates the patient. The second problem is, it's distracting, usually taking the most highly trained professional, he's distracted with securing an airway, confirming that it works. And then reconfirming it works, distracting him or her from why the patient originally went into cardiac arrest. So now let's pretend that the airway is established, and you're directing air to the lungs, you have a second problem, the ventilations during CPR decreased blood flow. So it's simple the way we normally meant to breathe, we suck air into our lungs, right, and that helps with venous return, which enhances the next heartbeat or chest compression. When someone's not breathing on their own. We reverse the mechanism, we push air into their lungs, and it has the opposite effect. Instead of enhancing blood flow. It impedes it, that positive pressure in the chest prevents venous return, the next heartbeat or next chest compression is not as effective. So the solution they came up with, we're not gonna do anything. They stopped doing ventilation and airway management for by standards. And they came up with chest compression only CPR. In the emergency setting, they reduced the amount of ventilations by half, and they de emphasized airway management completely. So I thought there has to be a better way than doing nothing at all. And we came up with the mentor. The mentor is a two approach solution. We simplified airway management, we found a better way to ventilate during cardiac arrest. First, the airway. When you place a tube into somebody's mouth, it can go one of two places down the esophagus towards the stomach, down the trachea towards the lungs. Our solution have a tube that there's no wrong location, it can ventilate in the esophagus, it can ventilate in the trachea, it automatically determines its location, isolates the lungs accordingly, and directs air to the lungs. Great, not only that, it always monitors where it is. The next approach is the ventilation technique. As I mentioned CPR, it's simple. It's a pump, you push down on the chest, you want to push blood out, you release the chest you want blood to return, the more you can push out the better. The more that you release the negative pressure the recoil, the better. So what if you could use the positive pressure of a ventilation to enhance the chest compression. So imagine that as you're pushing on the chest, you deliver a ventilation synchronized with that chest compression that enhances the chest compression. When the chest recoils, ventilation stops, blood returns unimpeded. The combined device we have now an airway simply placed one press of a button it figures out where it is and then automatically begins synchronizing ventilations with chest compressions, fully automated system that anybody could deploy. So, one problem solved we now have an airway and a ventilation device. Now we have to say is this marketable? First thing is you have to dress is okay, can we deploy this? Is it fast? Is it safe? Can does it accurately detect where it's been placed? Does it cause any trauma when being placed? The next is affordability is the device price competitive with the current things on the market. This is not a reimbursement product currently. So we have to make sure we can get the same price point as our competitors. Usability goes beyond just ease of use. It has to be a device that streamlines into the current workflow. And what that means is I have to replace a device on an ambulance or a fire apparatus. They're not going to lug another piece of equipment Up 13 flights of stairs to carry through here pretty patient, excuse me, 350 pound patient back down, it's got to replace another piece of equipment, and they don't currently carry ventilators. So we incorporated suction into our device. Lastly, is effectiveness. We've proved in the animal model, we're comparable to the gold standard of care. And now we're gonna move into the clinical trial to prove our effectiveness in the clinical study. I think what's unique about the Ventura, it's not just one solution, it's a multiple solutions combined into an elegant device that changes the way we manage airway and ventilation during cardiac arrest in the emergency setting, I want to talk a little bit about the clinical study design that we're going to start this summer. When you when I talk to people at the meeting, and I start discussing, you know, the things that we've the hurdles that we've overcome, this is as big as the device design itself. Think about cardiac arrest, you have patients that could you could have a 22 year old NFL player who got tackled, and went into cardiac arrest because of a dysrhythmia. You could have an 80 year old female who died of natural causes in bed the night before, and it was found in the next morning. And that could be your patient or the control patient. One could be 30 minutes from Level Two Trauma Center, the other could be three hours for a community hospital. Designing a clinical study on a budget and timeline of a startup for cardiac arrest was extremely thoughtful, extremely difficult. And what we found was a very unique patient population that has a proven control set of data where they showed up to the hospital, we've got arterial blood gases, which show how well CPR was performed and how well cast exchange occurred during CPR in a reliable manner. And it took out a lot of the noise. Not only that they're all funneled to a single hospital, where we don't have to get IRB approval in entire city. So this is really simplified. The data that we have to collect for clinical trial starts this summer. The most exciting thing about this is this data is knowing can be used for FDA clearance for marketing purposes. We'll know within 50 patients if the animal data transferred into the human study, and this company is worth continuing going forward. Excuse me, skip this companies continue to fund and move forward with. I'm going to skip the slide and I'll talk about later. We just closed our series B led by strategic off to say that of our preferred stockholders, the two largest shareholders are strategics. We are funded through 2024 through the clinical study, and then we'll start looking at raising our commercialization round. And we're starting to live discussions now. Why would we be funded by strategics. So early on, and it has to do with the market. It's a unique market similar to the ED where you have your initial placements that go into high contact with cardiac arrest, paramedics, er physicians, or crash carts. From there. It expands to every hospital, every nursing home dental offices, and then finally we can envision a place where it's co located with the AED. So initial markets 1.5 billion goes to 5 billion and then total $15 billion market. colabs airway and ventilation simplified